StockData

Cartesian Therapeutics, Inc. (RNAC) stock

RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 1/30
$6.08−0.27 (-4.25%)

Close on Nov 16, 2026Market cap $183.95MP/E –Yield –

Cartesian Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

No ebitda figures for Cartesian Therapeutics

Cartesian Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Cartesian Therapeutics figures

See a number that looks wrong?